NOVIGO (Drug Delivery) Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $202M

  • Investors
  • 10

NOVIGO (Drug Delivery) General Information

Description

Operator of a transdermal drug and cosmetic development company intended to improve the quality of life. The company develops drugs using transdermal formulations, drug development using modern technology, and cosmetic development, enabling the healthcare industry to access the next generation of transdermal products.

Contact Information

Website
www.novigopharma.co.jp
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Industry-Academia Collaboration Center
  • 4-1, Kyudaishinmachi, Nishi-ku
  • Fukuoka, Fukuoka Prefecture 819-0388
  • Japan
Primary Industry
Drug Delivery
Other Industries
Personal Products
Vertical(s)
Beauty, Life Sciences
Corporate Office
  • Industry-Academia Collaboration Center
  • 4-1, Kyudaishinmachi, Nishi-ku
  • Fukuoka, Fukuoka Prefecture 819-0388
  • Japan

NOVIGO (Drug Delivery) Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NOVIGO (Drug Delivery) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series B) 11-May-2026 $202M Completed Product Development
4. Accelerator/Incubator 18-Jul-2025 Completed Product Development
3. Early Stage VC (Series A2) 25-Feb-2025 Completed Product Development
2. Early Stage VC (Series A) 02-Nov-2021 $1.73M $1.73M Completed Product Development
1. Accelerator/Incubator 22-Jan-2021 Completed Startup
To view NOVIGO (Drug Delivery)’s complete valuation and funding history, request access »

NOVIGO (Drug Delivery) Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B
Series A2
Series A 49 $4000000 $4000000 1x $4000000 19.84%
To view NOVIGO (Drug Delivery)’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

NOVIGO (Drug Delivery) Patents

  • 14

    Total Documents Applications and Grants

  • Total Patents Families

  • 1

    Granted

  • 8

    Pending

  • Expiring in next 12 mo

NOVIGO (Drug Delivery) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026126727-A1 Composition for transdermal absorption preparation and transdermal absorption preparation Pending 10-Dec-2024
WO-2026063376-A1 Composition containing high-purity hydrophobic ion pair Pending 17-Sep-2024
AU-2024356648-A1 Method for introducing target molecule into lipid vesicle and cell, and antibody dispersion preparation Pending 06-Oct-2023
EP-4789659-A1 Method for introducing target molecule into lipid vesicle and cell, and antibody dispersion preparation Pending 06-Oct-2023
WO-2025075115-A1 Method for introducing target molecule into lipid vesicle and cell, and antibody dispersion preparation Inactive 06-Oct-2023 A61K9/5068
To view NOVIGO (Drug Delivery)’s complete patent history, request access »

NOVIGO (Drug Delivery) Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NOVIGO (Drug Delivery) Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
JIC Venture Growth Investments Venture Capital Minority
Sagin Capital & Consulting Venture Capital Minority
Plug and Play Accelerator/Incubator
Tokyo Metropolitan Government Accelerator Accelerator/Incubator
JMTC Capital Corporate Venture Capital Minority
You’re viewing 5 of 10 investors. Get the full list »

Ready to get started?

Request a free trial

NOVIGO (Drug Delivery) FAQs

  • When was NOVIGO (Drug Delivery) founded?

    NOVIGO (Drug Delivery) was founded in 2021.

  • Where is NOVIGO (Drug Delivery) headquartered?

    NOVIGO (Drug Delivery) is headquartered in Fukuoka, Japan.

  • What is the size of NOVIGO (Drug Delivery)?

    NOVIGO (Drug Delivery) has 10 total employees.

  • What industry is NOVIGO (Drug Delivery) in?

    NOVIGO (Drug Delivery)’s primary industry is Drug Delivery.

  • Is NOVIGO (Drug Delivery) a private or public company?

    NOVIGO (Drug Delivery) is a Private company.

  • What is the current valuation of NOVIGO (Drug Delivery)?

    The current valuation of NOVIGO (Drug Delivery) is .

  • What is NOVIGO (Drug Delivery)’s current revenue?

    The current revenue for NOVIGO (Drug Delivery) is .

  • How much funding has NOVIGO (Drug Delivery) raised over time?

    NOVIGO (Drug Delivery) has raised $204M.

  • Who are NOVIGO (Drug Delivery)’s investors?

    JIC Venture Growth Investments, Sagin Capital & Consulting, Plug and Play, Tokyo Metropolitan Government Accelerator, and JMTC Capital are 5 of 10 investors who have invested in NOVIGO (Drug Delivery).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process